Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naive patients with rheumatoid arthritisVergleichende Studie zur Wirksamkeit und Sicherheit von Tofacitinib, Baricitinib, Upadacitinib und Filgotinib vs. Methotrexat bei DMARD-naiven Patienten mit rheumatoider Arthritis
- Other Titles
- Vergleichende Studie zur Wirksamkeit und Sicherheit von Tofacitinib, Baricitinib, Upadacitinib und Filgotinib vs. Methotrexat bei DMARD-naiven Patienten mit rheumatoider Arthritis
- Authors
- Sung, Yoon Kyoung; Lee, Young Ho
- Issue Date
- Nov-2021
- Publisher
- SPRINGER HEIDELBERG
- Keywords
- JAK inhibitors; Rheumatoid arthritis; Network meta-analysis; Upadacitinib; Filgotinib
- Citation
- ZEITSCHRIFT FUR RHEUMATOLOGIE, v.80, no.9, pp.889 - 898
- Indexed
- SCIE
SCOPUS
- Journal Title
- ZEITSCHRIFT FUR RHEUMATOLOGIE
- Volume
- 80
- Number
- 9
- Start Page
- 889
- End Page
- 898
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/140604
- DOI
- 10.1007/s00393-020-00889-x
- ISSN
- 0340-1855
- Abstract
- An assessment of the relative efficacy and tolerability of tofacitinib, baricitinib, upadacitinib, and filgotinib compared to those of methotrexate (MTX) was performed in disease-modifying antirheumatic drug (DMARD)-naive patients with rheumatoid arthritis (RA). We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) so as to examine the efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib, and MTX in DMARD-naïve RA patients. Four RCTs comprising 2185 patients met the inclusion criteria. The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that upadacitinib 15 mg had the highest probability of achieving the American College of Rheumatology 20% (ACR20) response rate, followed by baricitinib 4 mg, tofacitinib 5 mg, filgotinib 200 mg, and MTX. Tofacitinib, baricitinib, upadacitinib, and filgotinib treatments achieved significantly higher ACR50 and ACR70 responses compared to MTX. Tofacitinib 5 mg had the highest probability of achieving the ACR50 and ACR70 response rates, followed by upadacitinib 15 mg, baricitinib 4 mg, filgotinib 200 mg, and MTX. The safety analysis based on serious adverse events, adverse events (AEs), and withdrawals due to AEs revealed no statistically significant differences between the respective intervention groups. In conclusion, tofacitinib, baricitinib, upadacitinib, and filgotinib were effective treatment options for DMARD-naïve RA patients, suggesting a difference in efficacy and safety among the different JAK inhibitors.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/140604)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.